DK3096798T3 - Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem - Google Patents
Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem Download PDFInfo
- Publication number
- DK3096798T3 DK3096798T3 DK15740774.3T DK15740774T DK3096798T3 DK 3096798 T3 DK3096798 T3 DK 3096798T3 DK 15740774 T DK15740774 T DK 15740774T DK 3096798 T3 DK3096798 T3 DK 3096798T3
- Authority
- DK
- Denmark
- Prior art keywords
- callic
- angioedem
- hereditary
- plasma
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
- C12Y207/03002—Creatine kinase (2.7.3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21034—Plasma kallikrein (3.4.21.34)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929716P | 2014-01-21 | 2014-01-21 | |
| US201461944361P | 2014-02-25 | 2014-02-25 | |
| US201462021397P | 2014-07-07 | 2014-07-07 | |
| PCT/US2015/012212 WO2015112578A1 (en) | 2014-01-21 | 2015-01-21 | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3096798T3 true DK3096798T3 (da) | 2021-03-01 |
Family
ID=53681890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15740774.3T DK3096798T3 (da) | 2014-01-21 | 2015-01-21 | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11084884B2 (da) |
| EP (2) | EP3848057A1 (da) |
| JP (3) | JP6845012B2 (da) |
| KR (3) | KR102424183B1 (da) |
| CN (2) | CN116585468A (da) |
| AU (2) | AU2015209481C1 (da) |
| BR (1) | BR112016016916B1 (da) |
| CA (1) | CA2937329C (da) |
| DK (1) | DK3096798T3 (da) |
| EA (1) | EA038532B1 (da) |
| ES (1) | ES2856076T3 (da) |
| IL (3) | IL246864B (da) |
| MX (2) | MX2016009428A (da) |
| NZ (2) | NZ761006A (da) |
| PL (1) | PL3096798T3 (da) |
| PT (1) | PT3096798T (da) |
| WO (1) | WO2015112578A1 (da) |
| ZA (2) | ZA201605342B (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2521568B1 (en) | 2010-01-06 | 2018-07-25 | Dyax Corp. | Plasma kallikrein binding proteins |
| IL310186A (en) | 2011-01-06 | 2024-03-01 | Takeda Pharmaceuticals Co | KALLIKREIN PLASMA BINDING PROTEINS |
| KR102523810B1 (ko) | 2013-01-20 | 2023-04-21 | 다케다 파머수티컬 컴패니 리미티드 | 브래디키닌 매개 장애의 평가 및 치료 |
| CN105051068A (zh) | 2013-03-15 | 2015-11-11 | 戴埃克斯有限公司 | 抗血浆激肽释放酶抗体 |
| JP6757252B2 (ja) | 2013-10-21 | 2020-09-16 | ダイアックス コーポレーション | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| CA2937329C (en) | 2014-01-21 | 2022-05-31 | Dyax Corp. | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| CA2979713A1 (en) * | 2015-03-30 | 2016-10-06 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| DK3365685T3 (da) * | 2015-10-19 | 2021-03-01 | Dyax Corp | Immunoassay til påvisning af spaltet højmolekylært kininogen |
| BR112018011622A2 (pt) * | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
| WO2018053260A1 (en) | 2016-09-16 | 2018-03-22 | Dyax Corp. | Rna biomarkers for hereditary angioedema |
| CA3037154A1 (en) | 2016-09-16 | 2018-03-22 | Dyax Corp. | Protein biomarkers for diseases associated with the contact activation system |
| CA3079568A1 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| AU2018374219C1 (en) | 2017-12-01 | 2023-05-11 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
| AU2018394875B2 (en) | 2017-12-29 | 2023-08-03 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SHORT INTERFERENT RNA CONJUGATE, METHOD FOR PREPARATION AND USE THEREOF |
| US20220315929A1 (en) * | 2019-05-24 | 2022-10-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5444156A (en) | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0296171A4 (en) | 1986-03-03 | 1989-11-07 | Brigham & Womens Hospital | METHOD FOR EVALUATING NEPHROTOXICITY. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5795865A (en) | 1994-01-11 | 1998-08-18 | Dyax Corp. | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| ES2392073T3 (es) | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
| EP2311432B1 (en) | 2002-06-07 | 2014-12-24 | Dyax Corporation | Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
| WO2005075665A2 (en) | 2004-02-03 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1) |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| ES2682646T3 (es) | 2006-03-16 | 2018-09-21 | Dyax Corp. | Composiciones y métodos para el tratamiento de trastornos oftálmicos |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
| NZ582930A (en) * | 2007-07-20 | 2012-11-30 | Diamedica Inc | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| JP2010536883A (ja) | 2007-08-23 | 2010-12-02 | ジェンザイム・コーポレーション | カリクレイン阻害剤を用いた治療 |
| CA2744235A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| CN101928346B (zh) | 2009-07-31 | 2013-01-16 | 华中科技大学同济医学院附属同济医院 | 一种抗人组织激肽释放酶单克隆抗体及其制备 |
| EP2521568B1 (en) | 2010-01-06 | 2018-07-25 | Dyax Corp. | Plasma kallikrein binding proteins |
| IL310186A (en) | 2011-01-06 | 2024-03-01 | Takeda Pharmaceuticals Co | KALLIKREIN PLASMA BINDING PROTEINS |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| ES2718347T3 (es) | 2013-01-20 | 2019-07-01 | Dyax Corp | Evaluación, ensayos y tratamiento de trastornos mediados por pKal |
| KR102523810B1 (ko) | 2013-01-20 | 2023-04-21 | 다케다 파머수티컬 컴패니 리미티드 | 브래디키닌 매개 장애의 평가 및 치료 |
| CN105051068A (zh) | 2013-03-15 | 2015-11-11 | 戴埃克斯有限公司 | 抗血浆激肽释放酶抗体 |
| CA2937329C (en) | 2014-01-21 | 2022-05-31 | Dyax Corp. | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| CA2979713A1 (en) | 2015-03-30 | 2016-10-06 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
| MX2019002918A (es) * | 2016-09-16 | 2019-07-18 | Dyax Corp | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. |
-
2015
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active IP Right Grant
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
- 2015-01-21 EP EP20209536.0A patent/EP3848057A1/en active Pending
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active IP Right Cessation
- 2015-01-21 KR KR1020247006911A patent/KR20240033156A/ko active Application Filing
- 2015-01-21 MX MX2016009428A patent/MX2016009428A/es unknown
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en active Application Filing
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
-
2016
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
-
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
-
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
-
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US20210087293A1/en active Pending
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
-
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3303379T3 (da) | Tigit-bindende midler og anvendelser deraf | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3185854T3 (da) | Injicerbare opslæmninger og fremgangsmåder til fremstilling og anvendelse af disse | |
| DK3185868T3 (da) | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3201336T3 (da) | Fremgangsmåder til ekstrahering og oprensning af ikke-denaturerede proteiner | |
| DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3350201T3 (da) | Manipulerede fytaser og fremgangsmåder til anvendelse af samme | |
| DK3277270T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3127923T3 (da) | Fremgangsmåde til forbedring af oppløselighed af protein og peptid ved hjælp af immunoglobulin-fc-fragment-binding | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK2924093T3 (da) | Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse |